Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Offering $1.9M in Securities in Private Placement

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a definitive agreement to sell to investors an aggregate $1.9 million in securities in a private placement.

The closing of the offering is expected to take place on or about Oct. 18. Rodman & Renshaw was the exclusive placement agent for the offering.

Rosetta, which earlier this week announced a restructuring resulting in 35 job cuts, will sell an aggregate of 2,598,002 shares of its common stock at $.75 per share. Investors also will receive Series A warrants to purchase up to an aggregate of 2,598,002 shares of its common stock at an exercise price of $1 per share, and Series B warrants to purchase up to an aggregate of 1,299,001 shares of its common stock at an exercise price equal to the greater of $.01 or ILS.04 ($.01).

Rosetta is required to file a resale registration statement with the US Securities Exchange Commission within 20 days following the closing that covers the resale by investors of the shares and shares issuable upon exercise of the warrants.

The Series A warrants are exercisable immediately and have a term of five years. The Series B warrants will be automatically exercised on a cashless basis on the 11th trading day after the effective date of the resale registration statement, dependent on certain conditions based on the weighted average price of Rosetta's ordinary shares.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.